Vasoactive intestinal peptide (VIP) mediated inhibition of platelet aggregation has been demonstrated in rabbit platelets.' While the mechanism by which VIP inhibits aggregation is thought to be via a specific receptor linked to adenylate cyclase, platelet receptors for VIP have not yet been demonstrated. The current studies were designed to test whether VIP regulates aggregation in human platelets and to determine whether specific, high-affinity VIP receptors are expressed on platelet membranes.
[''-'I]VIP Binding Studies
Membranes (200 pg protein) were incubated at 17'C with 100-150 pM [ 1*51]VIP (SA = 647 Ci/g), in the absence or presence of competing unlabeled peptide, in a final volume 0.5 ml. Membrane-bound [ "'IIVIP was separated from free by filtration through Whatman GF/C filters presoaked in 0.3% polyethylenimine as described by O'Dorisio et al. ' Time course and temperature studies demonstrated steady-state binding from 30 to 90 minutes at 17°C. The percentage of total counts bound to membrane protein ranged from 18% to 31% with 61% to 82% of bound ligand representing specific binding. Specific binding increased linearly with increasing concentration (50 to 500 pg) of membrane protein. Kinetic parameters were determined by a nonlinear computer-assisted fit of the competitive binding data.'
Platelet Aggregation Studies
Peripheral blood was obtained from healthy volunteers and slowly dispensed into 5-ml polystyrene tubes containing citrate (4.5 ml blood + 0.5 ml citrate). Plateletrich plasma was prepared by centrifuging citrated blood at 25°C for six minutes at 400 X g. Platelet-poor plasma was obtained by recentrifuging the blood specimen 10 minutes at 1500 x g. Aliquots of platelet-rich plasma were stirred in siliconized glass cuvettes in a Bio/Data platelet aggregation profiler, Model PAP-3. PAF (l-alkyl-2-acetyl-glycero-3-phosphorylcholine) was purchased from Sigma and dissolved in modified Tyrode's solution5 containing 5 mg/ml bovine serum albumin. VIP was dissolved in Tyrode's solution containing 0.5% BSA and 0.005% bacitracin. Platelet-rich plasma was incubated 60 seconds with or without VIP before addition of PAF or ADP.
RESULTS AND CONCLUSIONS
The specific binding (total bound [ 'zsI]VIP minus label bound in the presence of 1 pM unlabeled VIP) increased linearly with membrane protein concentration. Computer analysis of the data from 12 separate experiments demonstrated a single class of high-affinity binding sites with a mean dissociation constant (K,) of 23 2 6.3 nM (FIG. 1) . PHI, glucagon, and GHRF competed less effectively for ["'IIVIP binding sites, exhibiting K,s of 254 2 51, 441 k 21 and 135 k 73 nM, respectively.
VIP effects on platelet aggregation were investigated as shown in TABLE 1. VIP inhibited PAF-induced platelet aggregation by 50%. PAF is a potent platelet aggregating agent: This phospholipid has been shown to inhibit cyclic AMP accumulation in intact platelets and to inhibit adenylate cyclase activity in membranes of rabbit and human platelets.' VIP stimulates adenylate cyclase in intact platelets' and thus VIPmediated inhibition of PAF-induced platelet aggregation may result from the opposing effects of VIP and PAF on adenylate cyclase.
In summary, platelet membranes have been shown to possess receptors for vasoactive intestinal polypeptide (VIP). Competitive binding experiments using 200 pg membrane protein demonstrated a K, of 23 k 6.3 nM for [ 1251]VIP with a B,,, of 3.9 2 1.1 nM. The binding of [ "'I]VIP to platelet membranes is highly specific; the homologous peptides, PHI, GHRF, and glucagon, have lower affinity than VIP. VIP antagonizes platelet aggregation induced by platelet-activating factor, but not ADPinduced aggregation. These results suggest that human platelets possess functional VIP receptors that modulate platelet aggregation.
